SUPNSUPERNUS PHARMACEUTICALS, INC.同业对比
SUPERNUS PHARMACEUTICALS, INC. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPN本股 | $2.5B#6 | — | 2.4x#1 | 3.5x#2 | 8.6%#6 | -152.2%#13 | -8.7%#2 | -3.7%#2 | -5.0%#2 | — | -3.6%#4 | — |
| PGEN | $2.8B#1 | — | 63.6x#13 | 286.0x#8 | 146.7%#2 | -98.6%#11 | -1141.1%#8 | -575.1%#13 | -91.2%#9 | — | — | — |
| IMNM | $2.7B#2 | — | 5.2x#8 | 395.0x#9 | -23.2%#8 | 27.5%#1 | -3228.8%#9 | -40.4%#8 | -72.8%#8 | — | — | — |
| IRON | $2.7B#4 | — | 4.1x#5 | — | — | -94.0%#9 | — | -32.9%#7 | -39.0%#4 | — | — | — |
| NRIX | $2.7B#3 | — | 6.6x#10 | 31.7x#3 | 54.0%#4 | -36.6%#6 | -340.2%#5 | -65.7%#11 | — | — | — | — |
| MLYS | $2.5B#5 | — | 4.6x#7 | — | — | 13.0%#2 | — | -28.1%#6 | -41.3%#5 | — | — | — |
| VRDN | $2.5B#7 | — | 3.8x#4 | 35.1x#4 | 23359.9%#1 | -26.9%#5 | -512.9%#6 | -51.7%#10 | -54.5%#6 | — | — | — |
| HRMY | $2.5B#8 | 13.7x#1 | 2.5x#2 | 2.8x#1 | 21.5%#5 | 9.1%#4 | 24.0%#1 | 15.9%#1 | 25.5%#1 | 4#1 | 32.4%#3 | — |
| VERA | $2.4B#9 | — | 5.9x#9 | — | — | -96.9%#10 | — | -73.5%#12 | -72.7%#7 | — | 36.8%#1 | — |
| NKTR | $2.3B#10 | — | 2.6x#3 | 42.2x#5 | -43.9%#9 | -37.8%#8 | -253.7%#4 | -18.2%#3 | -14.0%#3 | — | 33.6%#2 | — |
| SLS | $2.3B#11 | — | 16.9x#12 | — | -100.0%#10 | 13.0%#3 | — | -19.5%#5 | — | — | — | — |
| OCUL | $2.2B#13 | — | 4.3x#6 | 43.0x#6 | -18.5%#7 | -37.4%#7 | -519.8%#7 | -51.1%#9 | — | — | — | — |
| PVLA | $2.2B#12 | — | 10.3x#11 | 52.3x#7 | 65.3%#3 | -139.3%#12 | -90.2%#3 | -19.2%#4 | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议